Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease
Endoscopy · 01.06.2026 · 58 (06) · 595-607
DOI: 10.1055/a-2780-0706 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von Enrique Rodríguez de Santiago und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Madrid, Spain. Hauptthemen laut MEDLINE: Endoscopic Mucosal Resection, Esophageal Mucosa, Gastroesophageal Reflux. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Research grant FSEED 2020 Spanish Society of Digestive Endoscopy (SEED)..
Abstract (Originalsprache)
Background
Antireflux mucosal ablation (ARMA) is a novel endoscopic technique for gastroesophageal reflux disease (GERD) but has only been assessed in noncontrolled studies. The objective of this randomized controlled study was to evaluate its efficacy in patients with proton pump inhibitor (PPI)-responsive GERD.
Methods
We conducted a double-blind, sham endoscopy-controlled, randomized trial across 12 Spanish hospitals. Adults with PPI-responsive GERD and abnormal esophageal acid exposure time (AET > 6 %) were randomly assigned (1:1) to receive ARMA or sham endoscopy. The primary outcome was clinical success at 12 months, defined as a ≥ 50 % reduction in the GERD-Health-Related Quality of Life score. Inability to discontinue PPIs to allow symptom assessment was considered treatment failure. Secondary outcomes included PPI discontinuation, AET, manometric parameters, mucosal healing, and adverse events.
Results
Of 186 patients screened, 60 were included (ARMA 31; sham 29). At 12 months, clinical success was achieved in 16 patients (51.6 %) in the ARMA group and in 11 (37.9 %) in the sham group (P = 0.29; risk ratio 1.36, 95 %CI 0.76 to 2.42). No significant differences were observed in PPI discontinuation, AET, manometric findings, or mucosal healing. Postprocedural pain (27.3 % vs. 3.3 %) and dysphagia (45.5 % vs. 10.0 %) occurred more frequently in the ARMA group. No severe adverse events were recorded.
Conclusions
ARMA was not superior to sham endoscopy in improving GERD-related quality of life at 12 months in patients with PPI-responsive GERD, and was associated with a higher incidence of adverse events. These findings do not support its implementation in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Liver and Digestive Diseases Research Group, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
- Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
- Department of Medicine, Universidad de Alcalá, Madrid, Spain.
- Gastroenterology Department, Hospital Universitario de Navarra (HUN), Navarrabiomed Biomedical Research Center, Pamplona, Spain.
- Gastroenterology Department, "i+12 Research Institute," Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.
ORCID-Profile: Enrique Rodríguez de Santiago, Carlos Teruel Sánchez-Vegazo, Eduardo Albéniz, Amaia Arrubla Gamboa, José Carlos Marín-Gabriel, Pilar Díez Redondo, Alberto Herreros De Tejada, Ismael El Hajra Martínez, Fausto Riu Pons, Hugo Uchima, Pedro De María Pallarés
Förderung
- Research grant FSEED 2020 Spanish Society of Digestive Endoscopy (SEED).
Zitieren
APA
Rodríguez de Santiago, E., Teruel Sánchez-Vegazo, C., Albéniz, E., Estremera Arévalo, F., Arrubla Gamboa, A., Castel, I., Arribas Anta, J., Marín-Gabriel, J. C., Díez Redondo, P., Núñez Rodríguez, H., Herreros De Tejada, A., El Hajra Martínez, I., Riu Pons, F., Naves, J. E., Uchima, H., Marín, I., Duque Alcorta, J. M., Pérez Corte, D., De María Pallarés, P., …, & ECA-ARMA authors of the Mucosal Resection and Third-Space Endoscopy SEED Working Group (2026). Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease. Endoscopy, 58(06), 595-607. https://doi.org/10.1055/a-2780-0706
Vancouver
Rodríguez de Santiago E, Teruel Sánchez-Vegazo C, Albéniz E, Estremera Arévalo F, Arrubla Gamboa A, Castel I, et al. Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease. Endoscopy. 2026;58(06):595-607. doi:10.1055/a-2780-0706
BibTeX
@article{RodrguezdeSantiago2026,
author = {Rodríguez de Santiago, Enrique and Teruel Sánchez-Vegazo, Carlos and Albéniz, Eduardo and Estremera Arévalo, Fermín and Arrubla Gamboa, Amaia and Castel, Isabel and Arribas Anta, Julia and Marín-Gabriel, José Carlos and Díez Redondo, Pilar and Núñez Rodríguez, Henar and Herreros De Tejada, Alberto and El Hajra Martínez, Ismael and Riu Pons, Fausto and Naves, Juan Enrique and Uchima, Hugo and Marín, Ingrid and Duque Alcorta, José María and Pérez Corte, Daniel and De María Pallarés, Pedro and Pérez Enciso, Irene and García Suarez, Covadonga and Lorenzo-Zúñiga, Vicente and Nogales, Óscar and Muriel, Alfonso and Albillos, Agustín and ECA-ARMA authors of the Mucosal Resection and Third-Space Endoscopy SEED Working Group, ECA-ARMA authors of the Mucosal Resection and Third-Space Endoscopy SEED Working Group},
title = {Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {06},
pages = {595--607},
doi = {10.1055/a-2780-0706}
}
EUVIMED